Opioid Relapse & HIV Risk: 48 Versus 24 Weeks of Injectable Extended Release Naltrexone
Status:
Completed
Trial end date:
2020-07-31
Target enrollment:
Participant gender:
Summary
To address the question of the comparison of two courses of Vivitrol with differing lengths
in 130 HIV negative, consenting, opioid addicted patients who have completed inpatient
treatment. Participants will be randomized under double blind conditions to a 24 or 48-week
course of pharmacotherapy, along with bi-weekly drug counselling, over 48 weeks, with
follow-ups at weeks 60 and 72. The 24-week cohort will receive Vivitrol placebo injections in
weeks 24 to 48.